CD274 and neoplasm: Targeted delivery of circRHBDD1-specific siRNA via PLGA-PEG nanoparticles significantly suppressed tumor growth, enhanced the efficacy of anti-PD-L1 therapy, and reduced severe adverse effects in murine models (107).